Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family

Leukemia

Volumn 23, Issue 1, 2009, Pages 199-203

  Cazzaniga, G ^a   Lo Nigro, L ^b   Cifola, I ^c   Milone, G ^b   Schnittger, S ^d   Haferlach, T ^d   Mirabile, E ^b   Costantino, F ^d   Martelli, M P ^e   Mastrodicasa, E ^e   Di Raimondo, F ^b   Aversa, F ^e   Biondi, A ^a   Falini, B ^e  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^d MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD68 ANTIGEN; CLOFARABINE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; MYELOPEROXIDASE; NUCLEOPHOSMIN; THIOTEPA; TRANSCRIPTION FACTOR RUNX1; TREOSULFAN;

ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANEMIA; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CELL INFILTRATION; CHROMOSOME 3; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG INDICATION; FAMILIAL DISEASE; FEMALE; FEVER; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LABORATORY TEST; LETTER; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 58249122389     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.170     Document Type: Letter

References (16)

1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266.
2. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106: 1419-1422.
3. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biologic and clinical features. Blood 2007; 109: 874-885.
4. Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U. Different types of NPM1 mutations in children and adults: Evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia 2007; 21: 366-367.
5. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108: 1999-2005.
6. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175.
7. Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004; 351: 2403-2407.
8. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N et al Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-126.
9. Simon-Sanchez J, Scholz S, Fung HC, Matarin M, Hernandez D, Gibbs JR et al. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet 2007; 16: 1-14.
10. Liso A, Bogliolo A, Freschi V, Martelli MP, Pileri SA, Santodirocco M et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia 2008; 22: 1285-1289.
11. Pasqualucci L, Li S, Meloni G, Schnittger S, Gattenlohner S, Liso A et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? Leukemia advance online publication, 17 January 2008; doi:10.1038/sj.leu.2405093.
12. Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, Brown P et al NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: A comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008; 93 439-442.
13. Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B et al Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008; 93: 775-779.
14. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945-3950.
15. Glass DC, Gray CN, Jolley DJ, Gibbons C, Sim MR, Fritschi L et al. Leukemia risk associated with low-level benzene exposure. Epidemiology 2003; 14: 569-577.
16. Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21: 998-1004.